• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性乳腺癌的光动力疗法

Photodynamic Therapy in Primary Breast Cancer.

作者信息

Banerjee Shramana M, El-Sheikh Soha, Malhotra Anmol, Mosse Charles A, Parker Sweta, Williams Norman R, MacRobert Alexander J, Hamoudi Rifat, Bown Stephen G, Keshtgar Mo Rs

机构信息

Breast Unit and Royal Free London NHS Foundation Trust, London NW3 2QG, UK.

Division of Surgery and Interventional Science, University College London, London W1W 7TY, UK.

出版信息

J Clin Med. 2020 Feb 10;9(2):483. doi: 10.3390/jcm9020483.

DOI:10.3390/jcm9020483
PMID:32050675
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7074474/
Abstract

Photodynamic therapy (PDT) is a technique for producing localized necrosis with light after prior administration of a photosensitizing agent. This study investigates the nature, safety, and efficacy of PDT for image-guided treatment of primary breast cancer. We performed a phase I/IIa dose escalation study in 12 female patients with a new diagnosis of invasive ductal breast cancer and scheduled to undergo mastectomy as a first treatment. The photosensitizer verteporfin (0.4 mg/kg) was administered intravenously followed by exposure to escalating light doses (20, 30, 40, 50 J; 3 patients per dose) delivered via a laser fiber positioned interstitially under ultrasound guidance. MRI (magnetic resonance imaging) scans were performed prior to and 4 days after PDT. Histological examination of the excised tissue was performed. PDT was well tolerated, with no adverse events. PDT effects were detected by MRI in 7 patients and histology in 8 patients, increasing in extent with the delivered light dose, with good correlation between the 2 modalities. Histologically, there were distinctive features of PDT necrosis, in contrast to spontaneous necrosis. Apoptosis was detected in adjacent normal tissue. Median follow-up of 50 months revealed no adverse effects and outcomes no worse than a comparable control population. This study confirms a potential role for PDT in the management of early breast cancer.

摘要

光动力疗法(PDT)是一种在预先给予光敏剂后利用光产生局部坏死的技术。本研究调查了PDT用于影像引导下原发性乳腺癌治疗的性质、安全性和疗效。我们对12例新诊断为浸润性导管癌且计划接受乳房切除术作为首次治疗的女性患者进行了I/IIa期剂量递增研究。静脉注射光敏剂维替泊芬(0.4mg/kg),随后通过在超声引导下经皮间质放置的激光光纤给予递增的光剂量(20、30、40、50J;每个剂量3例患者)。在PDT治疗前和治疗后4天进行MRI(磁共振成像)扫描。对切除组织进行组织学检查。PDT耐受性良好,未出现不良事件。7例患者通过MRI检测到PDT效应,8例患者通过组织学检测到PDT效应,效应程度随给予的光剂量增加,两种检测方式之间具有良好的相关性。组织学上,与自发性坏死相比,PDT坏死有明显特征。在相邻正常组织中检测到凋亡。50个月的中位随访显示无不良反应,结果不比可比的对照组人群差。本研究证实了PDT在早期乳腺癌治疗中的潜在作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a77c/7074474/83608948d576/jcm-09-00483-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a77c/7074474/398ab7acbbc7/jcm-09-00483-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a77c/7074474/2a40dc6b3499/jcm-09-00483-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a77c/7074474/83608948d576/jcm-09-00483-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a77c/7074474/398ab7acbbc7/jcm-09-00483-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a77c/7074474/2a40dc6b3499/jcm-09-00483-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a77c/7074474/83608948d576/jcm-09-00483-g003.jpg

相似文献

1
Photodynamic Therapy in Primary Breast Cancer.原发性乳腺癌的光动力疗法
J Clin Med. 2020 Feb 10;9(2):483. doi: 10.3390/jcm9020483.
2
Preclinical comparison of mTHPC and verteporfin for intracavitary photodynamic therapy of malignant pleural mesothelioma.mTHPC与维替泊芬用于恶性胸膜间皮瘤腔内光动力治疗的临床前比较。
Eur Surg Res. 2006;38(3):333-9. doi: 10.1159/000094028. Epub 2006 Jun 19.
3
Efficacy and safety of continuous low-irradiance photodynamic therapy in the treatment of chest wall progression of breast cancer.连续低剂量光动力疗法治疗乳腺癌胸壁转移的疗效与安全性
J Surg Res. 2014 Dec;192(2):235-41. doi: 10.1016/j.jss.2014.06.030. Epub 2014 Jun 24.
4
Minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated photosensitizer PEG-m-THPC.使用聚乙二醇化光敏剂PEG-m-THPC通过光动力疗法对大鼠盆腔中的卵巢癌进行微创减瘤。
Br J Cancer. 1999 Oct;81(4):631-7. doi: 10.1038/sj.bjc.6690740.
5
Defining the therapeutic window of vertebral photodynamic therapy in a murine pre-clinical model of breast cancer metastasis using the photosensitizer BPD-MA (Verteporfin).在使用光敏剂BPD-MA(维替泊芬)的乳腺癌转移小鼠临床前模型中定义椎体光动力疗法的治疗窗口。
Breast Cancer Res Treat. 2010 Jan;119(2):325-33. doi: 10.1007/s10549-009-0356-7. Epub 2009 Mar 5.
6
MRI assessment of treatment delivery for interstitial photodynamic therapy of high-grade glioma in a preclinical model.在临床前模型中,对高级别胶质瘤间质光动力治疗的治疗实施情况进行磁共振成像评估。
Lasers Surg Med. 2018 Jul;50(5):460-468. doi: 10.1002/lsm.22744. Epub 2017 Oct 11.
7
Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.一种用于前列腺癌光动力治疗的新型钯-细菌脱镁叶绿素(WST09)光敏剂在正常犬前列腺中的临床前研究。
Photochem Photobiol. 2002 Oct;76(4):438-45. doi: 10.1562/0031-8655(2002)076<0438:PSINCP>2.0.CO;2.
8
Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy.结合血管和细胞靶向方案可提高光动力疗法的疗效。
Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1216-26. doi: 10.1016/j.ijrobp.2004.08.006.
9
Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2.通过将靶向维替泊芬递送至由归巢肽介导至血管内皮生长因子受体-2的实验性脉络膜新生血管来进行选择性光动力疗法。
Arch Ophthalmol. 2004 Jul;122(7):1002-11. doi: 10.1001/archopht.122.7.1002.
10
Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.镥莫替沙芬介导的间质光动力疗法用于局部复发性前列腺癌患者的I期试验的更新结果。
J Environ Pathol Toxicol Oncol. 2006;25(1-2):373-87. doi: 10.1615/jenvironpatholtoxicoloncol.v25.i1-2.230.

引用本文的文献

1
Engineered bacteria for near-infrared light-inducible expression of cancer therapeutics.用于癌症治疗药物近红外光诱导表达的工程菌。
Nat Cancer. 2025 Apr;6(4):612-628. doi: 10.1038/s43018-025-00932-3. Epub 2025 Mar 17.
2
Facile Synthesis of Pyridyl Rosamines as Potential Photosensitizers.作为潜在光敏剂的吡啶基玫瑰胺的简便合成
Int J Mol Sci. 2025 Feb 10;26(4):1482. doi: 10.3390/ijms26041482.
3
Quantitative Changes in MicroRNAs in Blood Serum and Lymph after Photodynamic Therapy in Experimental Breast Cancer.实验性乳腺癌光动力治疗后血清和淋巴中微小RNA的定量变化

本文引用的文献

1
The role of photodynamic therapy on multidrug resistant breast cancer.光动力疗法在多药耐药乳腺癌中的作用。
Cancer Cell Int. 2019 Apr 11;19:91. doi: 10.1186/s12935-019-0815-0. eCollection 2019.
2
Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes.冷冻手术治疗原发性乳腺癌及其生物学影响和临床结局。
Int J Clin Oncol. 2019 Jun;24(6):608-613. doi: 10.1007/s10147-019-01448-4. Epub 2019 Apr 13.
3
Photodynamic therapy: A hot topic in dermato-oncology.光动力疗法:皮肤肿瘤学中的热门话题。
Bull Exp Biol Med. 2025 Jan;178(3):360-362. doi: 10.1007/s10517-025-06336-8. Epub 2025 Feb 13.
4
Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications.肿瘤微环境中的生物力学:从生物学功能到潜在临床应用
Exp Hematol Oncol. 2025 Jan 11;14(1):4. doi: 10.1186/s40164-024-00591-7.
5
Self-reporting photodynamic nanobody conjugate for precise and sustainable large-volume tumor treatment.自报告光动力纳米抗体偶联物用于精确和可持续的大容量肿瘤治疗。
Nat Commun. 2024 Aug 13;15(1):6935. doi: 10.1038/s41467-024-51253-5.
6
Influence of Photodynamic Therapy with Subsequent Surgical Treatment of Experimental Breast Cancer on Quantitative Changes in miRNAs in a Mesenteric Lymph Node.光动力疗法联合后续手术治疗实验性乳腺癌对肠系膜淋巴结中 microRNA 定量变化的影响。
Bull Exp Biol Med. 2024 Jun;177(2):271-273. doi: 10.1007/s10517-024-06171-3. Epub 2024 Aug 1.
7
Comparison of the Differences between Two-Photon Excitation, Upconversion, and Conventional Photodynamic Therapy on Cancers in In Vitro and In Vivo Studies.双光子激发、上转换与传统光动力疗法对癌症的差异在体外和体内研究中的比较
Pharmaceuticals (Basel). 2024 May 21;17(6):663. doi: 10.3390/ph17060663.
8
Photodynamic therapy for cancer: mechanisms, photosensitizers, nanocarriers, and clinical studies.癌症的光动力疗法:作用机制、光敏剂、纳米载体及临床研究。
MedComm (2020). 2024 Jun 22;5(7):e603. doi: 10.1002/mco2.603. eCollection 2024 Jul.
9
Oestrogen receptor positive breast cancer and its embedded mechanism: breast cancer resistance to conventional drugs and related therapies, a review.雌激素受体阳性乳腺癌及其内在机制:乳腺癌对常规药物和相关疗法的耐药性,综述。
Open Biol. 2024 Jun;14(6):230272. doi: 10.1098/rsob.230272. Epub 2024 Jun 19.
10
Magnetic Resonance Imaging in Breast Cancer Tissue In Vitro after PDT Therapy.光动力疗法后乳腺癌组织的体外磁共振成像
Diagnostics (Basel). 2024 Mar 6;14(5):563. doi: 10.3390/diagnostics14050563.
Oncol Lett. 2019 May;17(5):4085-4093. doi: 10.3892/ol.2019.9939. Epub 2019 Jan 16.
4
RFA experiences, indications and clinical outcomes.经皮射频消融治疗的经验、适应证和临床结果。
Int J Clin Oncol. 2019 Jun;24(6):603-607. doi: 10.1007/s10147-019-01423-z. Epub 2019 Mar 11.
5
Anti-VEGF Monotherapy Versus Photodynamic Therapy and Anti-VEGF Combination Treatment for Neovascular Age-Related Macular Degeneration: A Meta-Analysis.抗 VEGF 单药治疗与光动力疗法及抗 VEGF 联合治疗新生血管性年龄相关性黄斑变性:Meta 分析。
Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4307-4317. doi: 10.1167/iovs.17-23747.
6
High-intensity focused ultrasound in the treatment of breast tumours.高强度聚焦超声治疗乳腺肿瘤
Ecancermedicalscience. 2018 Jan 10;12:794. doi: 10.3332/ecancer.2018.794. eCollection 2018.
7
A Review of Photodynamic Therapy for Neoplasms of the Head and Neck.头颈部肿瘤的光动力疗法评价。
Adv Ther. 2018 Mar;35(3):324-340. doi: 10.1007/s12325-018-0659-3. Epub 2018 Feb 7.
8
Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.乳腺癌对新辅助化疗耐药的机制
N Engl J Med. 2017 Dec 7;377(23):2287-2289. doi: 10.1056/NEJMcibr1711545.
9
Trends and predictions to 2020 in breast cancer mortality in Europe.欧洲乳腺癌死亡率的趋势和预测到 2020 年。
Breast. 2017 Dec;36:89-95. doi: 10.1016/j.breast.2017.06.003. Epub 2017 Oct 4.
10
Photodynamic-Immune Checkpoint Therapy Eradicates Local and Distant Tumors by CD8 T Cells.光动力免疫检查点治疗通过 CD8 T 细胞根除局部和远处肿瘤。
Cancer Immunol Res. 2017 Oct;5(10):832-838. doi: 10.1158/2326-6066.CIR-17-0055. Epub 2017 Aug 29.